Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone

被引：23

作者：

Ciniselli, Chiara Maura ^{[1
]}

De Bortoli, Maida ^{[2
]}

Taverna, Elena ^{[2
]}

Varinelli, Luca ^{[2
]}

Pizzamiglio, Sara ^{[1
]}

Veneroni, Silvia ^{[3
]}

Bonini, Chiara ^{[4
]}

Orlandi, Rosaria ^{[5
]}

Verderio, Paolo ^{[1
]}

Bongarzone, Italia ^{[2
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Unit Med Stat Biometry & Bioinformat, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Lab Prote, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Biomarkers Unit, Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Lab Med, Milan, Italy

[5] Fdn IRCCS Ist Nazl Tumori, Mol Targeting Unit, Milan, Italy

来源：

EXPERT REVIEW OF PROTEOMICS | 2015年 / 12卷 / 06期

关键词：

benign breast disease; BMP6; breast cancer; early diagnosis; erytroferrone; erytropoiesis; erytropoietin; hepcidin; IL-6; inflammation; iron metabolism; BONE MORPHOGENETIC PROTEINS; SERUM HEPCIDIN; ANEMIA; IRON; INFLAMMATION; PREVALENCE; CARCINOMA; CORRELATE; SURVIVAL; LEVEL;

D O I：

10.1586/14789450.2015.1099436

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

引用

页码：695 / 701

页数：8

共 34 条

[1] Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? [J].

Alarmo, Emma-Leena ;

Kallioniemi, Anne .

[2] Bravais-Pearson and Spearman correlation coefficients: meaning, test of hypothesis and confidence interval [J].

Artusi, R ;

Verderio, P ;

Marubini, E .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (02) :148-151

[3] Cancer-related anemia and recombinant human erythropoietin - an updated overview [J].

Bohlius, J ;

Weingart, O ;

Trelle, S ;

Engert, A .

NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (03) :152-164

[4]

Camaschella C, 2008, COMMENT HAEMATOLOGIC, V93, P1473

[5]

Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.3.CO

[6]

2-G

[7] Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD [J].

Casanovas, Guillem ;

Mleczko-Sanecka, Katarzyna ;

Altamura, Sandro ;

Hentze, Matthias W. ;

Muckenthaler, Martina U. .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2009, 87 (05) :471-480

[8]

D'Auria L, 1997, EUR CYTOKINE NETW, V8, P383

[9] Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification [J].

Durigovaa, Anna ;

Lamy, Pierre-Jean ;

Thezenas, Simon ;

Pouderoux, Stephane ;

Montels, Frederic ;

Romieu, Gilles ;

Gutowski, Marian ;

Jacot, William .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (09) :1833-1841

[10]

Enko D, 2013, BRIT J HAEMATOL, V161, P639

← 1 2 3 4 →